Lipoprotein(a), pronounced "L-P-little-a," is a genetically inherited particle in the blood that independently increases the risk of heart attack, stroke, and aortic valve disease. Roughly one in five adults has an elevated level. The number is set largely at birth and does not respond to diet, exercise, or standard statin therapy.
Most men have never been tested for it. Including men whose fathers had early heart disease. That is the gap this article is here to close.
What is Lp(a)?
Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) bolted onto it. The extra protein makes the particle more likely to drive plaque formation, to encourage clotting, and to promote inflammation inside arteries. Three pathologic mechanisms in one molecule.
Levels are 80 to 90 percent determined by a single gene (LPA). Whatever level you have at age 5 is essentially the level you have at 55. It is one of the few cardiometabolic markers that is genuinely fixed.
Why Lp(a) matters
Elevated Lp(a) is among the most common inherited cardiovascular risk factors in the world. The data is consistent:
- Men with Lp(a) over 50 mg/dL have roughly double the lifetime cardiovascular risk of men with normal levels.
- Lp(a) over 180 mg/dL approaches a quadrupling of risk and is strongly associated with calcific aortic stenosis.
- The effect is independent of LDL, ApoB, hsCRP, and the rest of the standard panel. Two men with identical lipid profiles can have radically different real-world risk if one has elevated Lp(a) and the other does not.
This is the kind of risk that does not announce itself. It tracks silently behind a normal-looking cholesterol panel and shows up as a cardiac event in the late forties or fifties.
What counts as elevated
We use three tiers:
- Optimal: under 30 mg/dL (or under 75 nmol/L).
- Elevated: 50 mg/dL to 180 mg/dL.
- Very high: over 180 mg/dL (over 430 nmol/L).
Lab unit reporting is inconsistent. Older assays report mg/dL, newer ones report nmol/L. They are not interchangeable. Ask your clinician which units the lab is using.
Why you have probably never had it tested
Lp(a) was identified in 1963. The data linking it to cardiovascular events has been solid for over two decades. Major cardiology societies have recommended universal one-time screening for years.
Adoption in primary care is poor for three reasons. First, the number is inherited and "non-modifiable," which historically made clinicians hesitant to order a test they could not directly treat. Second, the standard preventive guidelines have only recently added it. Third, insurance coverage has lagged the science.
None of those reasons hold up. The number changes management even when it does not move. A high Lp(a) means aggressive control of the levers you can move.
What to do when Lp(a) is elevated
There is no medication that lowers Lp(a) into normal range yet. Several Lp(a)-specific drugs are in Phase 3 trials and may reach the clinic in the next few years. Until then, the management strategy is aggressive control of every other modifiable risk factor:
- Drive ApoB lower than standard targets. The conventional ApoB goal of under 90 mg/dL is for average-risk patients. For elevated Lp(a), we aim for under 70, often under 60.
- Statins are still indicated, even though they do not move Lp(a) directly. The ApoB lowering is what compensates.
- PCSK9 inhibitors (alirocumab, evolocumab) lower Lp(a) by about 20 to 30 percent and lower ApoB substantially. Worth considering when standard therapy is not enough.
- Aggressive blood pressure control. Plaque biology gets worse with hypertension regardless of the lipid driver.
- Smoking cessation, glucose control, weight on visceral fat. The multipliers are real.
- Aspirin. Selectively. Lp(a) is prothrombotic, and there is a subgroup of patients for whom low-dose aspirin makes sense. A clinician decides who.
The framing we use: a high Lp(a) is a tax on every other cardiovascular variable. You pay it by being more disciplined about everything you can move.
Family history matters
If you have a first-degree relative who had a heart attack, stroke, or coronary bypass before age 60, your pretest probability of elevated Lp(a) is meaningfully higher. Half of early cardiac events in the absence of obvious lifestyle drivers trace back to inherited lipid abnormalities, and Lp(a) is the most common of them.
If a parent or sibling has been told they have "high cholesterol" or "familial hypercholesterolemia," your Lp(a) test moves from optional to essential.
How we order and interpret Lp(a) at Vane
Lp(a) is on every Vane Baseline panel. One draw, one number, lifetime answer. We pair the result with the rest of the lipid and inflammation picture and write the protocol against the combined risk, not against the highest single marker.
For men who come back with elevated levels, the conversation shifts immediately to aggressive secondary prevention. That sometimes means starting a statin a decade earlier than a clinician without the Lp(a) data would have. It almost always means lower target numbers on the markers we can move.
The bottom line
Lp(a) is the closest thing in cardiovascular medicine to a one-time decisive test. The number is genetically set, clinically meaningful, and actionable through indirect routes even when no Lp(a)-specific drug is available.
Order it once. Read it correctly. Build the rest of your prevention strategy with the number in mind. The men who do this in their thirties end up in their sixties with very different outcomes than the men who never knew the number existed.
